Dated: March 28, 2000.

### L. Robert Lake,

Director of Regulations and Policy, Center for Food Safety and Applied Nutrition. [FR Doc. 00–9570 Filed 4–17–00; 8:45 am] BILLING CODE 4160–01–F

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Part 510

# New Animal Drugs; Change of Sponsor Address

**AGENCY:** Food and Drug Administration

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor address for International Nutrition, Inc.

**DATES:** This rule is effective April 18, 2000.

### FOR FURTHER INFORMATION CONTACT:

Thomas J. McKay, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0213.

### SUPPLEMENTARY INFORMATION:

International Nutrition, Inc., 6664 "L" St., Omaha, NE 68117, has informed FDA of a change of sponsor address to 7706 'I' Plaza, Omaha, NE 68127. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) to reflect the change of sponsor address.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A), because it is a rule of "particular applicability." Therefore, it is not subject to congressional review requirements in 5 U.S.C. 801–808.

### List of Subjects in 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

### PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by revising the entry for "International Nutrition, Inc." and in the table in paragraph (c)(2) by revising the entry for "043733" to read as follows:

# § 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

\* \* \* \*

(c) \* \* \*

(1) \* \* \*

Firm name and address				Drug labeler code		
*	*	*	*	*	*	*
International Nutrition, Inc., 7706 'I' Plaza, Omaha, NE 68127			043733 *	*	*	*

(2) \* \* \*

	Drug labeler	peler code Firm name and address			e and address	dress	
*	*	*	*	*	*	*	
043733	*	*	Internationa *	al Nutrition, Inc., 7706	l' Plaza, Omaha, NE 681 *	27	

Dated: March 17, 2000.

### Claire M. Lathers,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. [FR Doc. 00–9574 Filed 4–17–00; 8:45 am]

BILLING CODE 4160-01-F

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 520

# Oral Dosage Form New Animal Drugs; (S)-methoprene

**AGENCY:** Food and Drug Administration, HHS.

ACTION: Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect

approval of a new animal drug application (NADA) filed by Wellmark International. The NADA provides for oral use of (S)-methoprene for the prevention and control of flea populations.

**DATES:** This rule is effective April 18, 2000.

### FOR FURTHER INFORMATION CONTACT:

Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–7540.

**SUPPLEMENTARY INFORMATION:** Wellmark International, 1000 Tower Rd., suite

245, Bensenville, IL 60106, filed NADA 141–162 that provides for use in dogs, 9 weeks of age and older and 4 pounds body weight or greater, for the prevention and control of flea populations. (S)-methoprene prevents and controls flea populations by preventing the development of flea eggs but does not kill adult fleas. Concurrent use of insecticides may be necessary for adequate control of adult fleas. NADA 141–162 is approved as of January 24, 2000, and the regulations are amended in 21 CFR part 520 by adding new § 520.1390 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for 5 years of marketing exclusivity beginning January 24, 2000, because no active ingredient (including any ester or salt of the drug) has been previously approved in any other application filed under section 512(b)(1) of the act.

The agency has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

### List of Subjects

### 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

### 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amended as follows:

#### PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding an entry for "Wellmark International" and in the table in paragraph (c)(2) by numerically adding an entry for "011536" to read as follows:

# § 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

(c) \* \* \*

(1) \* \* \*

Firm name and address				Drug labeler code			
*	*	*	*	*	*	*	
Wellmark Interna	itional, 1000 Tower Ro	l., suite 245, Bensenville,	, IL 011536				
*	*	*	*	*	*	*	

(2) \* \* \*

	Drug labele	r code	Firm name and address			
*	*	*	*	*	*	*
011536			Wellmark Int 60106	ernational, 1000 Tow	ver Rd., suite 245, Bens	enville, IL
*	*	*	*	*	*	*

# PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

- 3. The authority citation for 21 CFR part 520 continues to read as follows: **Authority:** 21 U.S.C. 360b.
- 4. Section 520.1390 is added to read as follows:

### § 520.1390 (S)-methoprene.

- (a) Specifications. Each capsule contains 154, 308, or 462 milligrams (mg) of (S)-methoprene.
- (b) *Sponsor*. See No. 011536 in § 510.600(c) of this chapter.
  - (c) [Reserved]
- (d) Conditions of use—(1) Amount. Capsules are given orally, once per week at the recommended minimum dosage of 10 mg of (S)-methoprene per pound of body weight (22 mg/kilograms).
- (2) Indications for use. For oral use in dogs, 9 weeks of age and older and 4 pounds body weight or greater, for the prevention and control of flea populations. (S)-methoprene prevents and controls flea populations by preventing the development of flea eggs but does not kill adult fleas. Concurrent use of insecticides may be necessary for adequate control of adult fleas.

Dated: March 20, 2000. **Stephen F. Sundlof,** 

Director, Center for Veterinary Medicine. [FR Doc. 00–9575 Filed 4–17–00; 8:45 am]

BILLING CODE 4160-01-F

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Parts 510 and 520

### Oral Dosage Form New Animal Drugs; Change of Sponsor

**AGENCY:** Food and Drug Administration, HHS.

ACTION: Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the change of sponsor for a new animal drug application (NADA) from Merial Ltd., to Vetoquinol N.—A., Inc.

**DATES:** This rule is effective April 18, 2000.

### FOR FURTHER INFORMATION CONTACT:

Thomas J. McKay, Center for Veterinary

Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0213.

SUPPLEMENTARY INFORMATION: Merial Ltd., 2100 Ronson Rd., Iseline, NJ 08830–3077, has informed FDA that it has transferred the ownership of, and all rights and interests in, the approved NADA 113–510 (phenylbutazone granules) to Vetoquinol N.–A., Inc., 2000 chemin Georges, Lavaltrie (PQ), Canada, J0K 1HO. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c) and 520.1720b(b) to reflect the change of sponsor.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to congressional review requirements in 5 U.S.C. 801–808.

### List of Subjects

### 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

### 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amended as follows:

### PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding an entry for "Vetoquinol N.–A., Inc.," and in the table in paragraph (c)(2) by numerically adding an entry for "059320" to read as follows:

# § 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

(c) \* \* \*

(c) \* \* \* (1) \* \* \*

Firm name and address				Drug labeler code		
*	*	*	*	*	*	*
Vetoquinol N.–/ J0K 1H0	A., Inc., 2000 chemin G	eorges, Lavaltrie (PQ),	Canada, 059320			
*	*	*	*	*	*	*

(2) \* \* \*

-	Drug labele	er code	Firm name and address			
*	*	*	*	*	*	*
059320			Vetoquinol J0K 1H0	NA., Inc., 2000 cher	min Georges, Lavaltrie	(PQ), Canada,
*	*	*	*	*	*	*

# PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

### § 520.1720b [Amended]

4. Section 520.1720b *Phenylbutazone* granules is amended in paragraph (b) by

removing "050604" and by adding in its place "059320".

Dated: March 17, 2000.

### Claire M. Lathers,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. [FR Doc. 00–9573 Filed 4–17–00; 8:45 am]

BILLING CODE 4160-01-F

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

### 21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Hemoglobin Glutamer-200 (bovine)

**AGENCY:** Food and Drug Administration, HHS.